Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients’ involvement in specific therapies decision-making by unknown
RESEARCH ARTICLE Open Access
Is shared decision-making vanishing at the
end-of-life? A descriptive and qualitative
study of advanced cancer patients’
involvement in specific therapies
decision-making
Yvan Beaussant1,2,3*, Florence Mathieu-Nicot2,3,4, Lionel Pazart2, Christophe Tournigand5, Serge Daneault6,
Elodie Cretin2,3, Aurélie Godard-Marceau2, Aline Chassagne2, Hélène Trimaille2, Carole Bouleuc7, Patrice Cuynet4,
Eric Deconinck8 and Régis Aubry1,2,3
Abstract
Background: Little is known about what is at stake at a subjective level for the oncologists and the advanced
cancer patients when they face the question whether to continue, limit or stop specific therapies. We studied
(1) the frequency of such questioning, and (2) subjective determinants of the decision-making process from the
physicians’ and the patients’ perspectives.
Methods: (1) All hospitalized patients were screened during 1 week in oncology and/or hematology units of five
institutions. We included those with advanced cancer for whom a questioning about the pursuit, the limitation
or the withholding of specific therapies (QST) was raised. (2) Qualitative design was based on in-depth interviews.
Results: In conventional units, 12.8 % of cancer patients (26 out of 202) were concerned by a QST during the
study period. Interviews were conducted with all physicians and 21 advanced cancer patients. The timing of this
questioning occurred most frequently as physicians estimated life expectancy between 15 days and 3 months.
Faced with the most frequent dilemma (uncertain risk-benefit balance), physicians showed different ways of
involving patients. The first two were called the “no choice” models: 1) trying to resolve the dilemma via a technical
answer or a “wait-and-see” posture, instead of involving the patients in the questioning and the thinking; and 2),
giving a “last minute” choice to the patients, leaving to them the responsibility of the decision. In a third model,
they engaged early in shared reflections and dialogue about uncertainties and limits with patients, proxies and
care teams. These schematic trends influenced patients’ attitudes towards uncertainty and limits, as they were
influenced by these ones. Individual and systemic barriers to a shared questioning were pointed out by physicians
and patients.
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Conclusions: This study indicate to what extent these difficult decisions are related to physicians’ and patients’
respective and mutually influenced abilities to deal with and share about uncertainties and limits, throughout the
disease trajectory. These insights may help physicians, patients and policy makers to enrich their understanding of
underestimated and sensitive key issues of the decision-making process.
Keywords: Neoplasms, Decision making, Uncertainty, Ethics, Physician-patient relations, Defense mecanisms,
Withholding treatment, Advance care planning, Chemotherapy, Palliative care
Background
Cancer is the main cause of death in economically devel-
oped countries and the second in developing countries
[1, 2]. The length and quality of life of these patients has
considerably improved in the last years, thanks to new
therapies and improvements in supportive care [3–5].
However, when the disease progresses and becomes re-
fractory to treatments, physicians and patients face the
question of whether to pursue, limit or withhold anti-
cancer therapies [6].
Specific therapies (ST) used to control the evolution of
advanced cancers are generally chemotherapies, and less
frequently radiotherapies. When validated therapies fail
to control the disease, it becomes unlikely that further
ST will have superior effectiveness than uniquely sup-
portive care [7–9]. Conversely, it has been shown that
early palliative care in advanced pulmonary cancers is
associated with an increased survival and quality of life
[10, 11]. Fewer of these patients received chemotherapies
in the last weeks of life [8]. In other advanced cancer, re-
cent findings also support early palliative care [12]. Cur-
rently, the prescription of chemotherapies in the last
weeks of life tends to be considered a negative outcome
for the quality of end-of-life care. It is associated with in-
creased emergency room admissions and hospital
deaths, as well as to lower access to palliative care ser-
vices [9, 13]. However, several studies show that the use
of chemotherapies in the last weeks of life in advanced
cancer patients is widespread [9, 13, 14] and increasing
[15]. On average, these retrospective studies indicate that
about 20 % of cancer patients had received chemother-
apy during their last month of life.
It is likely that this paradox reflects the complexity of
the decision to pursue, limit or stop ST in these situa-
tions. Loss of hope or sense of abandonment that pa-
tients may experience when ST have to be stopped are
likely to interfere with medical or institutional determi-
nants [11, 16, 17]. However, studies conducted to under-
stand factors underlying such decisions remain rare,
and, while highlighting the importance of subtle interac-
tions between physicians and patients, they generally re-
port only the physicians’ (and sometimes the nurses’)
points of view [14, 18–22]. Furthermore, these studies
mainly focus on the decision itself and less frequently on
the prior questionings and deliberating process. To our
knowledge, the questioning about the pursuit, the limita-
tion or the withholding of ST (QST), from the compared
physicians’ and the patients’ perspectives, has not yet
been prospectively studied.
We present the results of a study exploring (1) the fre-
quency of the questioning about the pursuit, the limita-
tion or the withholding of ST in advanced cancer
patients, and (2) the determinants and modalities of
these questionings from the compared physicians’ and
the patients’ perspectives, with a focus on the patients’
involvement.
Methods
We conducted a prospective multi-centre observational
study in five various institutions located in Paris and
East of France: two university hospitals (one oncology
unit in Paris and one hematology unit in Besançon), one
general hospital (oncology / hematology unit of Colmar),
one cancer centre (Oncology, in Nancy) and one private
hospital (oncology, in Dijon). Patients were included
from January to May 2011. Inclusion criteria were the
following: adult patients, with advanced cancer or
hematological malignancy, hospitalized during the time
of the study, for whom the referent physician was ques-
tioning the pursuit, the limitation or the withdrawal of
ST at the time of the study or had such a questioning
within the two weeks preceding the investigation. The
study was approved by the regional independent ethics
committee (Comité de Protection des Personnes Grand
Est II) under the number 10/580.
Epidemiologic approach
The study included two different stages. First, an epi-
demiological and descriptive stage, in which we screened
all hospitalized patients, during a given week in each
centre, and identified and characterized those who
matched the inclusion criteria. Department characteris-
tics and institutional organization of the decision were
collected using a first questionnaire. For eligible patients,
patient characteristics and individual organization of the
decision were anonymously collected using a second
questionnaire. Data collected with these questionnaires
for the present analysis are shown in Tables 1 and 2.
Beaussant et al. BMC Palliative Care  (2015) 14:61 Page 2 of 12
The only exclusion criteria at this stage were pre-existing
guidelines or research protocols establishing therapeutic
action. For practical reasons, outpatients were not in-
cluded. Statistical descriptive analysis was performed by
the Clinical Investigation Centre (CIC) of Besançon, by
the mean of the SAS software for Windows, version 9.1
(SAS Institut, Inc., Cary, NC).
Qualitative analysis
The second stage aimed to understand the determinants
and modalities of the questioning through semi-directed
interviews with physicians and patients. Qualitative
methodology was selected in order to access informa-
tion on physicians’ and patients’ experiences which
could not be obtained through a quantitative design,
as well as to compare their points of view. Eligible
patients were informed of the study and their signed
consent was asked. Exclusion criteria concerned pa-
tients unable to be interviewed (poor general condi-
tion, patient discharged at time of interview), and
patients perceived by the referent physician as psy-
chologically unable to handle the interview. Interviews
with the referent physician directly approached the
determinants and modalities of their QST, whereas
with patients, this specific questioning was used only
if they were explicitly aware of it (semi-directive topic
lists are shown in annex 1 and 2, respectively). If not,
patients were interviewed about their general percep-
tion of the ST decision process, their involvement in
the decisions, and the influence of their relationship
with physicians, team and proxies on decisions.
YB (physician) interviewed the majority of the physi-
cians, and FMN (psychologist) the majority of the pa-
tients. For some of the interviews these roles were
reversed, in order to compare the two approaches. Mean
duration of the interviews was 30 and 60 min for the
physicians and the patients respectively. All the inter-
views were audiotaped and anonymously transcribed,
taking into account non-verbal expression of emotions.
We conducted qualitative analysis according to the
grounded theory model [23]. Verbatim transcribed from
the interviews were thematically analyzed, using Atlas.ti
6.2 software. Generated codes led to defined specific
categories, and then conceptual theory explaining inter-
actions between physicians and patients who were
questioned. The main two researchers confronted their
respective coding throughout the process of analysis in
order to achieve constant consensus and to ensure accur-
acy of emerging categories. We chose to conduct inter-
views with all the physicians, and with the maximum of
patients included in the epidemiological section of the
study. The saturation of concepts was applied and even-
tually reached. Definitions of emerging codes and themes
were written with typical examples from the interviews
to ensure clarity in communicating meaning. We used
Beauchamp and Childress’ definitions of ethical princi-
ples to describe value conflicts faced by physicians [24].
We addressed these recognized criteria for qualitative
research: credibility, concordance, auditability, and con-
firmability [25]. Credibility was assessed by regular
debriefing of the data collectors with a multidisciplinary
team drawing expertise from health sciences, sociology,
psychology, philosophy, and ethics, and by independent
coding and analysis by the investigators. Concordance
was assessed through line-by-line analysis of the inter-
view transcripts and by providing extensive examples of
the data. Detailed coding and memos written throughout
the analysis enhanced auditability, enabling an exam-
ination of the “decision trail” used. Consistency of the
investigators’ independent coding was examined and
confirmed by the research team. A professional trans-
lator translated the quotes that we eventually chose
to illustrate our results.
Results
Descriptive results
Frequency of the questioning
Among 839 cancer patients hospitalized in the five
centres during the inclusion week, 29 were concerned
by the QST of their physician (3.4 %). In conventional
Table 1 Distribution of the questionings about further specific therapies among the different centres
Investigation
centre
Speciality Number of beds Frequency of the QST: nb of included patients/nb of
hospitalized patients during the inclusion period (%)
Nb of
patients
interviewedConventional Ambulatorya Total Conventional Ambulatorya Total
University Hospital Haematology 39 14 53 4 / 41 (9.7) 1 / 99 (1) 5 / 140 (3.5) 5
Cancer centre Medical Oncology 46 52 98 3 / 62 (4.8) 0 / 247 (0) 3 / 309 (0.9) 1
University Hospital Medical Oncology 23 27 50 7 / 38 (18.4) 1 / 136 (0.7) 8 / 174 (4.5) 5
Private clinic Medical Oncology-RT 31 19 50 6 / 28 (21.4) 0 / 22 (0) 6 / 50 (12) 5
General Hospital Onco-haematology 23 35 58 6 / 33 (18.2) 1 / 133 (0.7) 7 / 166 (4.2) 5
162 141 303 26 / 202 (12.8) 3 / 637 (0.4) 29 / 839 (3.4) 21
QST questioning about specific therapies, nb number, RT radiotherapy
aAmbulatory includes day and week hospitalization
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and intensive care units, excluding day and week
hospitalization units, this proportion reached 12.8 % (26
out of 202). Table 1 presents the distribution of patients
concerned by the questioning according to their investi-
gation centre and the type of unit they were hospitalized
in. Among the 29 patients identified, we could conduct
all the interviews with the referent physicians (n = 17)
and 21 with the patients. All participants (both physi-
cians and patients) gave signed informed consent before
taking part. Reasons why eight patients were not inter-
viewed are the following: three were too physically ill,
three had been discharged at the time of the interviews,
one did not speak French, finally, a physician decided to
exclude one of his patients because she was considered
too anxious and to be maintaining an unrealistic hope
for cure. Five physicians were interviewed two times,
two physicians were interviewed three times, and one
physician was interviewed four times.
Patient characteristics
Patients included were 12 men and 17 women, with a
median age of 68 (range 43–80). Time from diagnosis to
inclusion date was 3.6 years (range 0.8–186.4 months).
Twenty patients were receiving ST at time of the inclu-
sion. For seven other patients, ST had been withheld for
a mean time of 3.5 months (range 1–13). The last two
patients had never received any ST. Characteristics of
the diseases and the clinical situations are presented in
Table 2.
Qualitative findings
Three kind of uncertainty led the interviewed physicians
to a QST: 1) an uncertain risk-benefit balance; 2) a
discrepancy between therapeutic possibilities and pa-
tients’ preferences, i.e. unfavorable risk-benefit balance
whereas the patient wished to continue treatments; 3)
the opposite discrepancy between therapeutic possibil-
ities and patients’ preferences, i.e. favorable risk-benefit
balance whereas the patient was unwilling to continue
treatment.
Facing the most frequent dilemma (uncertain risk-
benefit balance), physicians showed two predominant at-
titudes towards patients, that we named the “no choice”
models. The first attitude was trying to resolve the di-
lemma via a technical answer or a “wait-and-see” pos-
ture, instead of involving them in their questioning and
reflection (theme A). The second attitude was giving a
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“last minute” choice to the patient (theme B). Rarer, phy-
sicians described an early engagement in shared reflec-
tions and dialogue about uncertainties and limits with
patients, proxies and teams (theme C).
Theme A – First “no choice” model: trying to resolve
the dilemma with a technical answer or a “wait-and-
see” posture, instead of involving the patients in their
questioning.
Most physicians, before seeking to inform patients about
their uncertainty and involving them in the decision, waited
to resolve the dilemma between beneficence and non-
maleficence by either finding a technical answer that tem-
porally removed doubts, or waiting for the evolution of the
situation to impose an obvious decision.
He’s a patient who has high expectations from
treatments… We never brought it up [our doubts] with
him; neither had we ever sought to question such
things… No, we never brought it up directly with him.
Upon entering his room, the first thing he said was:
“See… It [tumour localized on the face] is growing!
Can we do something?” This was his question. And as
we had discussed it just before going into his room, we
could answer immediately: “Yes, we can try
something.” Physician 4, hematologist.
Based on physicians’ own words, it seemed that the
attitude of not addressing the issue of uncertainty with
patients was frequently the rule earlier in the disease tra-
jectory, when uncertainty between benefit and risk was
less crucial.
YB: Have you ever discuss the current situation of
uncertainty with the patient? MD: Not yet, because
we still are in a dynamic of treatments. Current
progression of the disease, while we were coming from
a cycle of chemotherapy… let’s say that this issue
hasn’t yet been addressed. Physician 27, oncologist.
Thus, the issue of uncertainty frequently emerged in
the discussions between physicians and patients as phy-
sicians realized that pursuing ST would no longer be an
option because ST and/or the patients were exhausted.
The decision to stop ST was described as difficult when
exhaustion of ST and exhaustion of the patient wasn’t
simultaneous. This was the case in the second and the
third kind of uncertainty described above. These situa-
tions could correspond to a lack of questioning from the
physicians themselves about the relevance of ST in ad-
vanced cancer, especially earlier in the disease trajectory.
YB: During the follow-up, did you discuss with this
patient the fact that chemotherapy should be stopped
at a certain point? MD: No, because until the third
line… It’s only realizing that the third line [of
chemotherapy] didn’t work, that we told ourselves
that it wasn’t reasonable to continue. YB: So, it
wasn’t discussed… Did the patient ever asked
questions about that? MD: No. YB: Does it happen
that patients sometimes ask about the possibility
that treatments should be stopped? MD: Rarely…
They’re always waiting for the next treatment.
Physician 8, oncologist.
Decisive action, rather than an involvement in a physi-
cian’s possible questioning, was also explicitly or implicitly
expected by the majority of patients.
Personally, I have always told the doctor: “it’s you who
decide, not me”. He’s the one who decides for my
treatment, it’s not me. He’s the one who knows. And
that’s it! I trust him; he’s a very good doctor. I trust
him totally! Patient 12.
YB: Were you able to talk with the team or the doctor
about these uncertainties, these issues you’re worried
about? P: I don’t want to talk about it… I mean… My
doubts… It’s true, obviously, there’s some doubts. But
let me tell you, they’re trying to address the problem;
they are doing their job. You know, I’m not someone
who’s very complicated at this level. Me, I take life as
it comes… Patient 9.
In general, there was a tacit and mutual adaptation be-
tween physicians and patients regarding the delivery of
information. Physicians adapted their information to the
patients’ will to be informed about treatment relevance
and goals, and patients adapted their demand of infor-
mation to the physicians’ propensity to communicate
about these issues. Facing a patient unwilling to get in-
volved in considerations concerning ST relevance, physi-
cians tended to spare them from their doubts. And
conversely, facing a physician who was reluctant to share
with them his/her uncertainties, patients generally relied
on his/her decisions without questioning their relevan-
cies or goals. Even though most of the patients left the
decisions to the doctor, most of them were also expect-
ing clear information about their situation. Discrepancies
between physician’s way to involve the patient and the
expectations of the latter occurred, generating dissatis-
faction and loss of trust.
P: Me? I don’t get into it, she’s the one who decides; not
me, I know nothing about it! FMN: Do you sometimes
give your opinion? P: No, no, I don’t give my opinion.
She doesn’t even ask for it! She told me: “we’ll do
chemo”, and she chose the treatment, it’s not me.
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FMN: Do you feel you had clear explanations about
your disease, your treatment? How do you see things?
P: I’d say she’s not very communicative… FMN: And
do you wish you had more time to discuss? P: That’s
not the problem… One has to worm it out from her.
When you ask her questions, she answers, but she’s not
open, like that… FMN: What questions do you ask? P:
Questions about trying to know… It’s difficult because
we, as patients, we know nothing about it. So if she
doesn’t want to answer, she doesn’t answer or she
avoids the question. [silence] Would another doctor
have given me another treatment…? I don’t know…
Patient 19.
Even when they chose not to share with patients their
existing or predictable uncertainty about treatment rele-
vance, physicians always included perceived patients’
preferences in their decisions. These preferences, some-
times explicit and more often tacit, were generally nomi-
nated as psychological dynamics that physicians could
perceive from the patients. Most of the time, it was
reflecting patients’ hope to keep the disease under con-
trol, and sometimes their weariness regarding their situ-
ation and/or treatments.
The patient is still fighting; I think she’s willing to
keep trying to find something that will improve her
situation. […] I can feel it. She’s never expressed it but
I can feel it. Physician 26, onco-hematologist.
In several cases, physicians argued that they would con-
tinue ST even if no or little benefits were expected from
it, because of the patient’s wish to continue the fight
against the disease. On the grounds that it would preserve
the patient’s hope, physicians spared them their reserva-
tions, and offered a treatment if any was available. If infor-
mation on the risks of inefficacy or toxicity was generally
delivered, these physicians remained allusive, in the best-
case scenario, about the limits to come of active treat-
ments. Sometimes, the question of therapeutic limitations
and end-of-life issues was ignored until the end.
YB: Did you discuss your doubts with the patient? MD:
Doubts on what? About the treatment outcome? Or the
likelihood of his general condition’s deteriorating?
Well… Vaguely! Generally, one tends to say: “well, if we
do nothing, we know where we’re going… Meaning often,
hit the wall. If we do something, you may get a chance
to avoid that. Well… avoid may sound overconfident,
but at least it could improve the situation.” So that’s it,
one leaves a… So for this patient, I think we discussed
in those terms. And I think he answered: “If you think
we can do something, let’s do it.” Physician 25,
onco-hematologist.
They rarely raise the question whether one day we’ll
have to stop… They’re always waiting for further
treatment. In general, when we know that we will
obviously do nothing more, we tend to use kind of
delaying tactic… It’s a bit hypocritical, but that’s how
it goes. They’re told: “we’re going to hospitalize you for
artificial feeding, to recover, etc. Personally, I mostly
treat ovarian cancer, and we proceed step by step.
When there is no more intestinal transit, there is no
more chemo, there are too many contraindications.
It’s done in steps: medical imaging, then you’re
hospitalized for rehydration because of your general
condition… Things speak from themselves; it’s not
overnight that we say “it's over”. And then, it becomes
a fait accompli because they’ve become weaker over
time. Some of them die here, but they ask few
questions. It’s unspoken but it is known. We don’t
force the issue by saying it’s over! We finally end up
understanding each other without using words.
Physician 8, oncologist.
Theme B – Second “no choice” model: giving a “last
minute” choice to the patient.
When facing uncertainty whether to continue or to
stop ST, some of the physicians considered that the
choice belonged to their patient.
MD: I’m wondering if it’s a good decision. […] On the
one hand, it’s difficult to take responsibility for the
fact that if I renounce, I take away her chances. On
the other hand, I know the dreadful prognosis of her
disease. So it’s very difficult! YB: What will the decision
finally rely upon, according to you? MD: I don’t know
yet. Maybe on what she tells me. Her wish, because I’m
going to try to speak to her as honestly as possible, not to
influence her response… Because it’s easy to influence a
response. Physician 29, oncologist.
Physicians discussed their influence on patients’
preferences in some interviews. They generally re-
ferred to the dominant model described above, in
which patients tended to rely on the physician’s de-
cision, agreeing to proposed therapies and usually
understanding the necessity to discontinue or stop
specific ST when they couldn’t be continued.
However, the nature of the choice left to patients when
they had to decide between continuing or withholding of
ST, was not discussed by physicians in the interviews.
Yet, several patients expressed the difficulty this could
represent for them.
If I have to make decisions? I don’t know if I could,
personally… I’d have the feeling I chose the wrong
thing…Patient 26.
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Another patient implied that between, on the one
hand, a therapeutic possibility inevitably associated with
hope as small as it may be and on the other hand,
therapeutic abstention, meaning the reality of the com-
ing death, there actually was no choice.
Anyway, either we do nothing, or we do something
that has a little chance! One must take a chance,
somehow… Personally, I am pragmatic: It’s yes, it’s no,
we’ll make it or we won’t… But if we don’t try…
Patient 9
In many situations, physicians seemed to use their influ-
ence to convince patients that further treatments were
justified until they began to doubt whether it would bene-
fit them, generally as cancer became far advanced. Then,
as the disease became unresponsive to treatments and/or
the patients’ general conditions worsened, and predicting
more or less consciously that death may be imminent,
physicians started to either convince them of the opposite,
or to give them the choice to continue or stop ST.
This “no choice” situation, before which some physi-
cians placed their patients, hampered an “informed” deci-
sion on the part of the latter, particularly since end-of-life
issues had generally not been previously discussed. Except
for two patients suffering from hematological malignan-
cies, for whom a curative goal was still expected in spite of
a questioning on pursuing or withholding ST because of
morbidity, all the physicians expressed that they told the
patients about the incurable nature of their cancer. How-
ever, fewer physicians expressed having shared with their
patients about the on-going questioning (18 of the 29 phy-
sicians, and 12 of the 21 whose patients could be inter-
viewed). Even fewer physicians expressed having earlier
discussed with their patients (not including the on-going
questioning) that ST might possibly be limited or stopped
at a certain point of the disease trajectory (7 and 4 re-
spectively, of the two groups described above). Finally,
only four physicians mentioned that they had discussed
about death or end-of-life preferences with their patients.
Two of these conversations had been initiated by patients
themselves.
From the patients’ point of view, incurability was gen-
erally understood, and they were often aware of disease
resistance to ST. However, half of the patients expressed
unrealistic expectations from ST compared to those of
their physicians. Only a third seemed aware of their phy-
sician’s questioning on therapeutic limitations. All the
patients wanted ST to be continued at the time of the
interview. Among them, four expressed ambivalence due
to apprehension of ST morbidity and/or weariness toward
active care of their disease. Several patients faced difficul-
ties expressing their fears or their doubts with their
physicians. Sharing these was sometime discouraged by
physicians, and thus they were unable to be taken into ac-
count of in the questioning about the goals of care.
I wish they could find a treatment that’s not too
difficult and that works, that’s it! […] I’ve already
told them twice: “I’m fed up… Anyway, I’ll stop
everything… we’ll see what happens!” “Oh no, we can’t
do that!” So, I said: “Yes, I know…” “No, no, I’m not
allowed”, he said, as if to say: “even if you wished…” I
talked about it twice […] not to provoke, but because
I’m fed up, you know, it just isn’t working!” Patient 26.
P: Yes I trust them, but still, I have some questions!
FMN: Yes? Which ones, for example? P: Is my 3rd
chemo going to do the same thing [pulmonary toxicity]
or are they going to change it again? That’s it…
Because I don’t want to be hospitalized for 10 days,
every 21 days… FMN: Do you get answers to that?
P: Not really… Because I have the feeling they don’t
really know…, that’s basically it… Patient 4.
I asked again this question, today: is it worthwhile? As he
[the physician] says, there’s always hope, since we haven’t
tried every treatment… But when I see myself like this…
It’s hard to imagine that my life will last a long time. […]
I think that we cling to any little thing, and if something
exists, we try, even if sometimes we just want to give up…
Even so, it’s hard to just give up. Patient 16.
Theme C - Early engagement in shared reflections
and dialogue about uncertainties and limits with pa-
tients, proxies and teams: complexity and subtlety of
shared decision-making.
As long as the dynamics of disease control through ST
was at stake, conversations between physicians and pa-
tients were dominated by the medical and technical
issues of treatments and were driven by the need to
maintain hope based on treatments. Many physicians
underlined contradictions in advanced cancer patients’
care: supporting patient autonomy while respecting her/
his limits and psychological integrity; not neglecting pa-
tients’ fears or needs, and anticipating end-of-life issues
while active treatments were still justified and made it
possible to easily avoid these topics; sharing their uncer-
tainties and treatment limits with patients, when they
expected reassurance and hope… These tensions were
considered as wearisome by most physicians. However,
some of them, belonging to the same investigation
centre, considered they were challenging communication
issues, implying anticipation and continuous adjustment.
Before deciding to begin chemotherapy, we discussed a
lot about the advantages and the disadvantages [with
the patient] … So I explained at lenght the risk-benefit
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balance without excessive valuation of chemotherapy,
and really, above all, taking into account Ms. B’s view,
and explaining the issues. So it wasn’t “Listen : here
are the response rates, here is the higher survival rate
with treatment, versus we do nothing and we do
palliative care”… it’s not as clear-cut as that, this kind
of discussion doesn’t help. No, I just involved her in
what we can do, what we cannot… the importance
of comfort care in parallel… She was aware of these
issues very early. Physician 12, oncologist.
These physicians frequently mentioned that anticipat-
ing uncertainties and the limits of treatment in the dis-
cussions with patients and with the care team was a
major issue of care. They considered that, by working
early, progressively and cautiously on this issue with pa-
tients, they allowed the emergence of benchmarks, or
thresholds beyond which pursuing an active stance
against the disease by means of ST would become inad-
equate. This encouraged mutual agreement based on the
respect of values, priorities or the quality of life concep-
tions of the patient. In their opinion, achieving this re-
quired personal thoroughness and rigor, as well as
interdisciplinary team, to comprehensively take into ac-
count the patient within his family system.
Efforts in communication are needed: the way of going
about things, verbal and non-verbal communication,
taking into account others around who may have in-
fluence, time management one’s own timing, and re-
specting the pace of the person in front of us, what he
says to other caregivers that he doesn’t say to us. […]
In the end, one could find it rather reassuring to apply
guidelines. But guidelines, either for undertaking or
desisting treatments, won’t solve the question of how
and when to discuss either with the patient. Physician
11, oncologist.
Yes, [these multidisciplinary meetings] help. They
bring me other points of view, especially those of the
caregivers who interact with the patients at different
moments of the day, not necessarily at the same time
as I do. It gives me the opportunity to know what
happened over the last few days, if I haven’t seen the
patient every day, and to see if my feeling is the same
as theirs, and how they consider things. So it is an
opportunity to have different notions in time and other
points of views. Physician 12, oncologist.
Conversely, interviews with physicians and patients
showed that a shared questioning about therapeutic lim-
itations and end-of-life issues was difficult and some-
times impossible to initiate when this was “up against
the wall”. For both of them, stopping ST was associated
with resignation to the coming death. When physicians
faced the clinical impossibility to continue ST and
looked forward to discuss these issues with patients
(often for the first time), either psychological defence
mechanisms or anguish about death seemed to hamper
both physicians’ and patients’ ability to value a “life-
after-ST”, and to identify issues making this “after” not
just a hopeless and morbid waiting time. These psycho-
logical defence mechanisms were identified in many of
the physician’s and patient’s words:
I told him: “We’re not doing chemo tomorrow.” And
then, he looked at me with horrified eyes, and told me:
“That’s not possible, if we don’t do chemo, I won’t be
alright!” So, I said “but you can see that you’re not
alright, now, despite the chemo!” So he was a little…
he hesitated, and then he answered: “No, no, I want
to do it! I can’t just not do it!”. That’s it, for him it
wasn’t even conceivable. Stopping treatment wasn’t
conceivable. I told him: “Listen, I can… If you want we
can do it, but it’s the last one!” Actually, I cheated a
bit; I gave in on that point, telling that we wouldn’t do
anymore [chemotherapy]. It was a bit stupid, because
he could have said the same the week after… and
what would I have done? Physician 18, oncologist.
P: I’d like to continue, but as long as… First of all, I’ve
not defecated for 10 days, and there is still no sign…
They’re trying their best to liberate the bowels, but that’s
it, that’s where we’re at. YB: Is this the reason why
chemotherapy is not being continued for the moment?
P: No, we’re still doing it… But you see, I was told it
would be long. For the previous time, it was already long,
because I didn’t defecate for 14 days… YB: Would you
need more discussion or explanations from your doctor
about the current situation? P: [whispering] There’s no
point… YB: Why? P: Because I very much hope, so there’s
no need to… to know too much… Patient 20.
Individual and systemic barriers to a shared questioning
Individual barriers
Barriers related to individual (caregivers’, patients’ or
proxies’) limits appeared to hinder a timely and sensitive
sharing about uncertainties and treatment limits, which
in turn influenced medical decision. It seemed these in-
dividual limits were related to the varying capacities each
to cope with disappointed hopes, which were at first
possible, then likely, and finally certain: hope to be
cured, to live longer, to release suffering for patients and
their families; hope to cure, to prolong life, to provide
answers and solutions for the physicians.
YB: Is this feeling of giving up strong, when treatments
are stopped? MD: Yes, I feel it intensely, because I was
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taught to heal people and not the other way round!
We’re not here to tell… We do it every day, but it’s
rarely easy. Physician 1, hematologist.
It’s a bit like giving up, since as soon as we don’t treat
the disease anymore, we know very well that it will
evolve towards a tragic end. Maybe it’s a kind of
personal failure statement too. One thinks “that’s it, I
can’t stabilize or slow the progression of the disease!”
But most of all, it’s the feeling towards the patient…
one feels that when one decides to stop, it’s a kind of
death sentence… That’s exactly what it is. Physician
26, onco-hematologist.
Patients and physicians facing a possible discontinu-
ation of ST seemed to experience individual suffering,
consisting of fear of death, anguish, and feelings of giv-
ing up, failure or guilt. Furthermore, the suffering of
each was likely to be mutually reinforced. Thus, frequent
avoidance of shared questioning about uncertainties,
helplessness and end-of-life issues seemed to be fostered
by a mutually reinforced refusal to “give up”, driven by a
mutually reinforced avoidance of suffering.
In contrast, some physicians considered that acknow-
ledging, accepting, and possibly sharing their emotional
involvement in these situations were part of their profes-
sional responsibilities, so that their decisions could re-
main centred on the patient’s interest.
One has to acknowledge that it’s one’s job, and that
this [end-of-life decision] is going to happen. But it’s
true that we get more attached to some patients, and
that’s natural […] I think that what matters most is
that we do our best, trying to keep an eye inside on
what relationship we may have with patients so that
decision remains fair. We can’t always keep control,
far from it, and that’s not the goal either. Not exposing
oneself is also important to avoid getting into feelings
of failure, etc. I’m quite aware of this, and I believe
that I’m quite conscious about how I get involved,
including on the emotional side. So it happens that,
sometimes, I let it go, and fortunately we have a
psychologist who helps to get it off one’s chest, when we
find it hard. Physician 10, oncologist.
Systemic barriers
In addition to individual barriers, physicians pointed out
systemic and/or institutional barriers that contributed to
the hindrance of in-depth questioning regarding uncer-
tainties and limits with the teams and the patients. They
named several obstacles: lack of time; lack of appre-
ciation of deliberative and reflexive time; lack of ap-
preciation of the information and support time with
patients and families; lack of communication and
ethical reflection training; and lack of psychological
support for caregivers.
MD: We do out-patient consultations early in the
morning, we hurry up to go see [hospitalized patients]
or determine a goal because our time is limited. And
sometimes we don’t have time… that’s it, our own time.
YB: How does this influence your decisions? MD: In
the sense that we don’t take the time to listen to what
the patient has to say, nor the time to explain. […] We
don’t take the time to let the patient set his/her pace,
and say things… Physician 21, oncologist.
Is it easier with experience? I’d say no, it’s less and less
easy, because we’re not psychologically supported
despite the difficult situations we may face, the bad
news we have to give… We might deliver very good
news, and 10 s later, we might announce death. So
these sudden turnaround situations for hospitalized
people or out-patients are difficult because we don’t
have an outlet; we don’t have anybody to speak to
about it with. Physician 1, hematologist.
We don’t have the words, we were not trained for that.
So we use everyday words without knowing if we’re… if
they’re the right words, if they’re fair according to the
psychological context. We were not trained for that…
Personally I wasn’t trained. So we blurt it straight out,
and we hurt… Physician 25, onco-hematologist.
Discussion
This study reports for the first time, to our knowledge,
(1) a prospective measurement of the prevalence of the
questioning about the relevance of ST in hospitalized
advanced cancer patients and (2) a mirror prospective
analysis of physicians’ and patients’ points of views con-
cerning the decision process. These questionings con-
cerned nearly 13 % of hospitalized patients. They were
rare in the day or week units, and we observed a hetero-
geneous distribution among the different centres.
The timings of these questionings were variable since
they could be initiated before any ST was started as well
as after several treatment lines, when no further treat-
ment was feasible. However, most of them occurred as
physicians estimated a life expectancy comprised be-
tween 15 days and 3 months. This timing seemed to rely
on clinical factors: cancer type and extension, its clinical
impact, the clinical background, previous and/or ex-
pected treatment efficacy and tolerance, or availability of
further treatments. Other factors emerged from our ana-
lysis of physicians’ and patients’ interviews: (1) individual
factors related to their respective capacity and propen-
sity to go into and share a questioning about knowledge
limits (uncertainty), controlling limits (helplessness), and
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life limits (death); (2) factors related to unit sub-cultures;
and thirdly, factors related to institutional constraints.
These results bring a deeper understanding to the sub-
jective determinants of the prescription of chemotherapy
already reported in other studies [16].
Appropriate timing for initiating shared questioning
with patients about treatment limitations (i.e. end-of-life
issues) has been widely debated in the last few years.
Our results show that physicians may adopt various pos-
tures, depending on patients’ limits as well as on theirs.
A mutual adaptation seems to occur, explaining that a
physician and a patient could be satisfied with the care
while end-of-life issues were never discussed, whereas
others had engaged such discussions earlier and benefi-
cially. However, discrepancies occurred, raising ethical
issues. Such ethical issues have been recently discussed
on the basis of a qualitative analysis of physicians’ and
nurses’ interviews in Germany [26]. Results reported by
Temel et al. showed that quality of life, psychological
consequences and length of life were improved in meta-
static pulmonary cancer patients as early palliative care,
in collaboration with oncological care, notably focused
on patients’ understanding of prognosis [10, 27, 28]. Sev-
eral studies revealed that many patients were able to
keep hope alive while acknowledging the terminal stage
of their disease, and that most of them were expecting
honest and precise information from their physicians,
given with empathy and sensitivity [17, 29–31]. However,
these discussions are difficult, and may be harmful for
patients in terms of quality of life and the psychological
impact [32]. Thus, they have to remain careful, tailored
to each patient, and contained in a professional frame-
work where communication training is essential [33, 34].
Indeed, results presented in this study show the com-
plexity and the subtlety of the patients’ involvement in
the decision process. We report the modalities of the
questioning, and even more of its sharing, that were
often sacrificed to a relational dynamic, mutually rein-
forced, focused on hope and “not giving up”. These re-
sults are consistent with the findings of Buiting et al.
[18], and allow a better understanding of the Western
countries’ concern, that terminal cancer care is increas-
ingly aggressive [9, 13–15, 35, 36]. We describe a domin-
ant model where physicians and patients faced a “no
choice” decision, when physicians were striving to resolve
the dilemma between beneficence and non-maleficence by
the means of two different ways. Firstly, by means of a
technical answer or a “wait-and-see” attitude letting the
evolution of the situation decide by itself. This way of
responding to uncertainty seemed favoured by the fact de-
scribed in other studies, that some patients were reluctant
to be involved and some physicians to involve them in the
decision process [19, 37–39]. And secondly, by deciding
to leave the choice between pursuing or discontinuation
of ST to the patient. This attitude, described elsewhere in
the literature, seems to match a minority of patients’ pref-
erences only [40–42], and is likely to put them in a diffi-
cult “no choice” position, where they have to choose
between inevitability of the death and potentially futile or
harmful (but “hope supporting”) treatment. In the other
decision-making model that we describe, the physicians
initiated early shared reflections and dialogue about uncer-
tainties and limits with patients, proxies and teams, allow-
ing the emergence of individual benchmarks, or thresholds
making it possible to guide the decision about the appro-
priate role of ST in a given situation. The relevance of such
an approach in clarifying specific goals of care for each
patient was thoughtfully discussed by Emanuel et al. [43].
The propensity of physicians to use this second way of
dealing with uncertainty seems to depend on how they
consider their professional role, and if, in addition to the
responsibility of being competent bio-clinicians, a psycho-
social role is assumed: helping patients and families to cope
with advanced or terminal disease [44]. This posture is
likely to be consistent with erratic trajectories of advanced
cancer patients, in which therapeutic options are multiple
and changing, as they were described by Kort et al. [20].
The main obstacle to implementing this model seems
to be related in this study, as in the literature, to a sys-
temic and cultural relational dynamic into which,
through ST, the need for hope is converted into fighting
the disease, and dealing with suffering is partly avoided
as long as ST remain available [18, 45, 46]. Mostly un-
conscious and mutually reinforced defense mechanisms
are at stake. They may protect each other from experien-
cing overwhelming distress in these situations. But they
also may divert attention and questionings from funda-
mental issues other than disease control in advanced
cancer patients, such as: appropriate pain and symptom
management; avoidance of a prolongation of life in un-
acceptable conditions because of unrealistic hope; pres-
ervation of self-determination; bereavement support;
and mediation in patient/family relationships [47]. Mul-
tidisciplinarity [48] and proxies’ integration [49] in end-
of-life discussions are essential to personalizing the care
of advanced cancer patients.
The interpretation of the results reported here must
take some limitations into account. First, the saturation
of concepts was applied and reached in a second step, as
we chose to conduct all the physicians’ interviews, and a
maximum of the eligible patients’ interviews. However,
even if patient sampling was not guided by the satur-
ation of concepts, we tested the validity of the emerging
models through a saturation of concepts a posteriori and
repeated cross analysis by our multidisciplinary research
team. Secondly, having included hematology patients
could be considered as a limitation, since a potential
curative goal remained for some of them, probably
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reinforcing the not-giving up attitude observed else-
where [50–52]. Nevertheless, the shared questioning
model that we developed still seemed to be valuable
even when concurrent with justified active treatment,
suggesting that it may be valid in both solid cancer and
hematological malignancies. Finally, the frequency of the
questioning is likely to underestimate the reality, as it
was recorded during one week only and excluded out-
patient consultations.
Conclusion
Personalized medicine is central to current public health
issues in economically developed countries. In oncology
and hematology, the term covers different realities, from
progress in targeted therapies to improvements in coord-
ination and in the networking of caregivers [6, 53]. Our
study highlights essential determinants of the decision-
making process of the pursuit, limitation or discontinu-
ation of ST in advanced cancer patients and the personal
and inter-personal ability to question and share about un-
certainty and limits in an ethical approach. Improvements
have to be made in the acknowledgement and the imple-
mentation of such an approach, without which personal-
ized medicine remains different from a patient centred
medicine.
Efforts still need to be developed and intensified in
several fields, including: initial and ongoing training of
caregivers working with cancer patients on ethical, com-
municational and end-of-life issues; developing a caring
environment allowing the implementation of a real
transdisciplinary approach and decision-making process;
giving value to deliberative and reflexive time, regarding
them as health care interventions integrated in the fi-
nancing system of care units; encouraging patients and
health care users to get information from and discuss
goals of care with their physician. Research on caring or
experiencing advanced cancer situations and end-of-life
should be developed and favoured, as important gaps re-
main in many fields, such as symptoms management,
understanding of seriously ill patients’ and their care-
givers’ needs depending on their cultural background,
decision process, or physicians’ and patients’ interactions
in the end-of-life context [54].
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